AbbVie's Deal with Apogee; Regenxbio Moves on Gene Therapy Drug | Stock Movers

الأصول والمواضيع المتأثرة

نبرة المقال

التأثير المتوقع على السوق

مسار الأدلة

دورة حياة التوقّع

• Free Analysis Rule Based Analysis ليس ذكاءً اصطناعياً SPCX Neutral 50% 6h
  أُنشئ في → 6 س → مُستبعَد

  Expired: not evaluated within 7 days of its 6h timeframe elapsing

يُسجَّل وقت النشر، ويُقيَّم تلقائياً بمجرد انتهاء النافذة الزمنية — دون أي تعديل.

المصدر الأصلي

On this episode of Stock Movers with Nathan Hager: - Apogee (APGE) shares are soaring on news AbbVie is closing in on a nearly $11 billion deal to buy inflammatory disease drug developer Apogee Therapeutics. That's also according to a Financial Times report. - Regenxbio (RGNX) shares are moving on news Regenxbio aligned with the FDA on next steps for a potential accelerated approval of Navsunli, a gene therapy for Mucopolysaccharidosis II, with the FDA confirming the company doesn’t need to conduct additional studies of the drug. - SpaceX (SPCX) is lower this morning, continuing its slide after its record IPO. (Source: Bloomberg)

اقرأ المقال كاملاً على Bloomberg

المقال الأصلي منشور بواسطة Bloomberg في يونيو 22, 2026. التحليل والرؤى المقدمة من AnalystMarkets AI.

المزيد من سردية SPCX

• 14:35 Space Exploration Technologies Corp (SPCX) Leads Fund’s Performance Following Historic Initial Public Offering Yahoo Finance
• 22:19 Stock Market Today, Aug. 7: Space Exploration Technologies Surges on Q2 Revenue Beat, Lockup Relief, and Terafab Update Yahoo Finance
• 21:24 S&P 500 Ends At Record High, Clocks Strongest Week Since April As Poor Jobs Data Calms Rate Hike Fear — SEZL, SPCX, RDW, PLTR, TTD In Focus Yahoo Finance
• 13:25 SpaceX's Next Big Test Is the $101 Billion (SPCX) Unlock: Live Q&A Bloomberg